Department of Hematology and Oncology; Center for Cancer Immune Therapy; University Hospital ; Herlev, Copenhagen, Denmark.
Department for Translational Dermato-Oncology (DKTK); Center for Medical Biotechnology (ZMB); University Hospital Essen; Universitätsstraße ; Essen, Germany.
Oncoimmunology. 2015 Jan 30;4(1):e968480. doi: 10.4161/21624011.2014.968480. eCollection 2015 Jan.
Tryptophan-2,3-dioxygenase (TDO) physiologically regulates systemic tryptophan levels in the liver. However, numerous studies have linked cancer with activation of local and systemic tryptophan metabolism. Indeed, similar to other heme dioxygenases TDO is constitutively expressed in many cancers. In the present study, we detected the presence of both CD8 and CD4 T-cell reactivity toward TDO in peripheral blood of patients with malignant melanoma (MM) or breast cancer (BC) as well as healthy subjects. However, TDO-reactive CD4 T cells constituted distinct functional phenotypes in health and disease. In healthy subjects these cells predominately comprised interferon (IFN)γ and tumor necrosis factor (TNF)-α producing Th1 cells, while in cancer patients TDO-reactive CD4 T-cells were more differentiated with release of not only IFNγ and TNFα, but also interleukin (IL)-17 and IL-10 in response to TDO-derived MHC-class II restricted peptides. Hence, in healthy donors (HD) a Th1 helper response was predominant, whereas in cancer patients CD4 T-cell responses were skewed toward a regulatory T cell (Treg) response. Furthermore, MM patients hosting a TDO-specific IL-17 response showed a trend toward an improved overall survival (OS) compared to MM patients with IL-10 producing, TDO-reactive CD4 T cells. For further characterization, we isolated and expanded both CD8 and CD4 TDO-reactive T cells . TDO-reactive CD8 T cells were able to kill HLA-matched tumor cells of different origin. Interestingly, the processed and presented TDO-derived epitopes varied between different cancer cells. With respect to CD4 TDO-reactive T cells, expanded T-cell cultures comprised a Th1 and/or a Treg phenotype. In summary, our data demonstrate that the immune modulating enzyme TDO is a target for CD8 and CD4 T cell responses both in healthy subjects as well as patients with cancer; notably, however, the functional phenotype of these T-cell responses differ depending on the respective conditions of the host.
色氨酸 2,3-双加氧酶(TDO)在肝脏中生理性地调节全身色氨酸水平。然而,许多研究将癌症与局部和全身色氨酸代谢的激活联系起来。事实上,与其他血红素加氧酶一样,TDO 在许多癌症中持续表达。在本研究中,我们在恶性黑色素瘤(MM)或乳腺癌(BC)患者以及健康受试者的外周血中检测到针对 TDO 的 CD8 和 CD4 T 细胞反应的存在。然而,TDO 反应性 CD4 T 细胞在健康和疾病中构成了不同的功能表型。在健康受试者中,这些细胞主要由产生干扰素(IFN)γ和肿瘤坏死因子(TNF)-α的 Th1 细胞组成,而在癌症患者中,TDO 反应性 CD4 T 细胞的分化程度更高,不仅在 MHC 类 II 限制肽的反应中释放 IFNγ和 TNFα,还释放白细胞介素(IL)-17 和 IL-10。因此,在健康供体(HD)中,Th1 辅助反应占主导地位,而在癌症患者中,CD4 T 细胞反应偏向于调节性 T 细胞(Treg)反应。此外,与产生 IL-10 的 TDO 反应性 CD4 T 细胞相比,具有 TDO 特异性 IL-17 反应的 MM 患者的总生存(OS)有改善的趋势。为了进一步表征,我们分离和扩增了 CD8 和 CD4 TDO 反应性 T 细胞。TDO 反应性 CD8 T 细胞能够杀死不同来源的 HLA 匹配的肿瘤细胞。有趣的是,不同癌细胞之间处理和呈现的 TDO 衍生表位不同。对于 CD4 TDO 反应性 T 细胞,扩增的 T 细胞培养物包含 Th1 和/或 Treg 表型。总之,我们的数据表明,免疫调节酶 TDO 是健康受试者和癌症患者的 CD8 和 CD4 T 细胞反应的靶点;然而,这些 T 细胞反应的功能表型取决于宿主的具体情况而不同。